Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy
Saved in:
| Hovedforfatter: | |
|---|---|
| Publication Date: | 2011 |
| Andre forfattere: | , , , , , , , , , |
| Format: | Article |
| Sprog: | eng |
| Source: | Repositório Institucional da UnB |
| Download full: | http://repositorio.unb.br/handle/10482/17627 |
Summary: | Background: Rhodium (II) citrate (Rh2(H2cit)4) has significant antitumor, cytotoxic, and cytostatic activity on Ehrlich ascite tumor. Although toxic to normal cells, its lower toxicity when compared to carboxylate analogues of rhodium (II) indicates Rh2(H2cit)4 as a promising agent for chemotherapy. Nevertheless, few studies have been performed to explore this potential. Superparamagnetic particles of iron oxide (SPIOs) represent an attractive platform as carriers in drug delivery systems (DDS) because they can present greater specificity to tumor cells than normal cells. Thus, the association between Rh2(H2cit)4 and SPIOs can represent a strategy to enhance the former’s therapeutic action. In this work, we report the cytotoxicity of free rhodium (II) citrate (Rh2(H2cit)4) and rhodium (II) citrate-loaded maghemite nanoparticles or magnetoliposomes, used as drug delivery systems, on both normal and carcinoma breast cell cultures. Results: Treatment with free Rh2(H2cit)4 induced cytotoxicity that was dependent on dose, time, and cell line. The IC50 values showed that this effect was more intense on breast normal cells (MCF-10A) than on breast carcinoma cells (MCF-7 and 4T1). However, the treatment with 50 μM Rh2(H2cit)4-loaded maghemite nanoparticles (Magh-Rh2(H2cit)4) and Rh2(H2cit)4-loaded magnetoliposomes (Lip-Magh-Rh2(H2cit)4) induced a higher cytotoxicity on MCF-7 and 4T1 than on MCF-10A (p < 0.05). These treatments enhanced cytotoxicity up to 4.6 times. These cytotoxic effects, induced by free Rh2(H2cit)4, were evidenced by morphological alterations such as nuclear fragmentation, membrane blebbing and phosphatidylserine exposure, reduction of actin filaments, mitochondrial condensation and an increase in number of vacuoles, suggesting that Rh2(H2cit)4 induces cell death by apoptosis. Conclusions: The treatment with rhodium (II) citrate-loaded maghemite nanoparticles and magnetoliposomes induced more specific cytotoxicity on breast carcinoma cells than on breast normal cells, which is the opposite of the results observed with free Rh2(H2cit)4 treatment. Thus, magnetic nanoparticles represent an attractive platform as carriers in Rh2(H2cit)4 delivery systems, since they can act preferentially in tumor cells. Therefore, these nanopaticulate systems may be explored as a potential tool for chemotherapy drug development. |
| _version_ | 1871442585494487040 |
|---|---|
| author | Carneiro, Marcella Lemos Brettas |
| author2 | Nunes, Eloiza da Silva Peixoto, Raphael Cândido Apolinário Oliveira, Ricardo G. Simões Lourenço, Luiza Helena Madia Silva, Izabel Cristina Rodrigues da Simioni, Andreza Ribeiro Tedesco, Antonio Claudio Souza, Aparecido R de Lacava, Zulmira Guerrero Marques Báo, Sônia Nair |
| author2_role | author author author author author author author author author author |
| author_browse | Báo, Sônia Nair Carneiro, Marcella Lemos Brettas Lacava, Zulmira Guerrero Marques Lourenço, Luiza Helena Madia Nunes, Eloiza da Silva Oliveira, Ricardo G. Simões Peixoto, Raphael Cândido Apolinário Silva, Izabel Cristina Rodrigues da Simioni, Andreza Ribeiro Souza, Aparecido R de Tedesco, Antonio Claudio |
| author_facet | Carneiro, Marcella Lemos Brettas Nunes, Eloiza da Silva Peixoto, Raphael Cândido Apolinário Oliveira, Ricardo G. Simões Lourenço, Luiza Helena Madia Silva, Izabel Cristina Rodrigues da Simioni, Andreza Ribeiro Tedesco, Antonio Claudio Souza, Aparecido R de Lacava, Zulmira Guerrero Marques Báo, Sônia Nair |
| author_role | author |
| bitstream.checksum.fl_str_mv | 47a2992b3dc1727454a5c9729cd6f0b5 1554fabdb52f4d7ad979cffae637115e |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 |
| bitstream.url.fl_str_mv | http://repositorio2.unb.br/jspui/bitstream/10482/17627/1/ARTIGO_FreeRhodiumCitrate.pdf http://repositorio2.unb.br/jspui/bitstream/10482/17627/2/license.txt |
| collection | Repositório Institucional da UnB |
| dc.contributor.author.fl_str_mv | Carneiro, Marcella Lemos Brettas Nunes, Eloiza da Silva Peixoto, Raphael Cândido Apolinário Oliveira, Ricardo G. Simões Lourenço, Luiza Helena Madia Silva, Izabel Cristina Rodrigues da Simioni, Andreza Ribeiro Tedesco, Antonio Claudio Souza, Aparecido R de Lacava, Zulmira Guerrero Marques Báo, Sônia Nair |
| dc.date.accessioned.fl_str_mv | 2015-02-11T12:24:05Z |
| dc.date.available.fl_str_mv | 2015-02-11T12:24:05Z |
| dc.date.issued.fl_str_mv | 2011 |
| dc.identifier.citation.fl_str_mv | CARNEIRO, Marcella Lemos Brettas, et al. Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy. Journal of Nanobiotechnology, v. 9, p. 11, 2011. Disponível em:<http://www.jnanobiotechnology.com/content/9/1/11>. Acesso em: 03 fev. 2015. |
| dc.identifier.uri.fl_str_mv | http://repositorio.unb.br/handle/10482/17627 |
| dc.language.iso.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Jornal de Nanobiotecnologia |
| dc.rights.driver.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:Repositório Institucional da UnB instname:Universidade de Brasília (UnB) instacron:UNB |
| dc.subject.keyword.pt_BR.fl_str_mv | Mamas - câncer - tratamento Quimioterapia |
| dc.title.en.fl_str_mv | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| dc.type.driver.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.status.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Background: Rhodium (II) citrate (Rh2(H2cit)4) has significant antitumor, cytotoxic, and cytostatic activity on Ehrlich ascite tumor. Although toxic to normal cells, its lower toxicity when compared to carboxylate analogues of rhodium (II) indicates Rh2(H2cit)4 as a promising agent for chemotherapy. Nevertheless, few studies have been performed to explore this potential. Superparamagnetic particles of iron oxide (SPIOs) represent an attractive platform as carriers in drug delivery systems (DDS) because they can present greater specificity to tumor cells than normal cells. Thus, the association between Rh2(H2cit)4 and SPIOs can represent a strategy to enhance the former’s therapeutic action. In this work, we report the cytotoxicity of free rhodium (II) citrate (Rh2(H2cit)4) and rhodium (II) citrate-loaded maghemite nanoparticles or magnetoliposomes, used as drug delivery systems, on both normal and carcinoma breast cell cultures. Results: Treatment with free Rh2(H2cit)4 induced cytotoxicity that was dependent on dose, time, and cell line. The IC50 values showed that this effect was more intense on breast normal cells (MCF-10A) than on breast carcinoma cells (MCF-7 and 4T1). However, the treatment with 50 μM Rh2(H2cit)4-loaded maghemite nanoparticles (Magh-Rh2(H2cit)4) and Rh2(H2cit)4-loaded magnetoliposomes (Lip-Magh-Rh2(H2cit)4) induced a higher cytotoxicity on MCF-7 and 4T1 than on MCF-10A (p < 0.05). These treatments enhanced cytotoxicity up to 4.6 times. These cytotoxic effects, induced by free Rh2(H2cit)4, were evidenced by morphological alterations such as nuclear fragmentation, membrane blebbing and phosphatidylserine exposure, reduction of actin filaments, mitochondrial condensation and an increase in number of vacuoles, suggesting that Rh2(H2cit)4 induces cell death by apoptosis. Conclusions: The treatment with rhodium (II) citrate-loaded maghemite nanoparticles and magnetoliposomes induced more specific cytotoxicity on breast carcinoma cells than on breast normal cells, which is the opposite of the results observed with free Rh2(H2cit)4 treatment. Thus, magnetic nanoparticles represent an attractive platform as carriers in Rh2(H2cit)4 delivery systems, since they can act preferentially in tumor cells. Therefore, these nanopaticulate systems may be explored as a potential tool for chemotherapy drug development. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | UNB_e8a3c43cff0ed9e83e72b63f2ed84697 |
| identifier_str_mv | CARNEIRO, Marcella Lemos Brettas, et al. Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy. Journal of Nanobiotechnology, v. 9, p. 11, 2011. Disponível em:<http://www.jnanobiotechnology.com/content/9/1/11>. Acesso em: 03 fev. 2015. |
| instacron_str | UNB |
| institution | UNB |
| instname_str | Universidade de Brasília (UnB) |
| language | eng |
| network_acronym_str | UNB |
| network_name_str | Repositório Institucional da UnB |
| oai_identifier_str | oai:repositorio.unb.br:10482/17627 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher.none.fl_str_mv | Jornal de Nanobiotecnologia |
| reponame_str | Repositório Institucional da UnB |
| repository.mail.fl_str_mv | repositorio@unb.br |
| repository.name.fl_str_mv | Repositório Institucional da UnB - Universidade de Brasília (UnB) |
| repository_id_str | |
| spelling | Carneiro, Marcella Lemos BrettasNunes, Eloiza da SilvaPeixoto, Raphael Cândido ApolinárioOliveira, Ricardo G. SimõesLourenço, Luiza Helena MadiaSilva, Izabel Cristina Rodrigues daSimioni, Andreza RibeiroTedesco, Antonio ClaudioSouza, Aparecido R deLacava, Zulmira Guerrero MarquesBáo, Sônia Nair2015-02-11T12:24:05Z2015-02-11T12:24:05Z2011CARNEIRO, Marcella Lemos Brettas, et al. Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy. Journal of Nanobiotechnology, v. 9, p. 11, 2011. Disponível em:<http://www.jnanobiotechnology.com/content/9/1/11>. Acesso em: 03 fev. 2015.http://repositorio.unb.br/handle/10482/17627Background: Rhodium (II) citrate (Rh2(H2cit)4) has significant antitumor, cytotoxic, and cytostatic activity on Ehrlich ascite tumor. Although toxic to normal cells, its lower toxicity when compared to carboxylate analogues of rhodium (II) indicates Rh2(H2cit)4 as a promising agent for chemotherapy. Nevertheless, few studies have been performed to explore this potential. Superparamagnetic particles of iron oxide (SPIOs) represent an attractive platform as carriers in drug delivery systems (DDS) because they can present greater specificity to tumor cells than normal cells. Thus, the association between Rh2(H2cit)4 and SPIOs can represent a strategy to enhance the former’s therapeutic action. In this work, we report the cytotoxicity of free rhodium (II) citrate (Rh2(H2cit)4) and rhodium (II) citrate-loaded maghemite nanoparticles or magnetoliposomes, used as drug delivery systems, on both normal and carcinoma breast cell cultures. Results: Treatment with free Rh2(H2cit)4 induced cytotoxicity that was dependent on dose, time, and cell line. The IC50 values showed that this effect was more intense on breast normal cells (MCF-10A) than on breast carcinoma cells (MCF-7 and 4T1). However, the treatment with 50 μM Rh2(H2cit)4-loaded maghemite nanoparticles (Magh-Rh2(H2cit)4) and Rh2(H2cit)4-loaded magnetoliposomes (Lip-Magh-Rh2(H2cit)4) induced a higher cytotoxicity on MCF-7 and 4T1 than on MCF-10A (p < 0.05). These treatments enhanced cytotoxicity up to 4.6 times. These cytotoxic effects, induced by free Rh2(H2cit)4, were evidenced by morphological alterations such as nuclear fragmentation, membrane blebbing and phosphatidylserine exposure, reduction of actin filaments, mitochondrial condensation and an increase in number of vacuoles, suggesting that Rh2(H2cit)4 induces cell death by apoptosis. Conclusions: The treatment with rhodium (II) citrate-loaded maghemite nanoparticles and magnetoliposomes induced more specific cytotoxicity on breast carcinoma cells than on breast normal cells, which is the opposite of the results observed with free Rh2(H2cit)4 treatment. Thus, magnetic nanoparticles represent an attractive platform as carriers in Rh2(H2cit)4 delivery systems, since they can act preferentially in tumor cells. Therefore, these nanopaticulate systems may be explored as a potential tool for chemotherapy drug development.Jornal de NanobiotecnologiaEste é um artigo Open Access distribuído sob os termos da Licença Creative Commons Attribution (http://creativecommons.org/licenses/by/2.0 ), que permite o uso irrestrito, distribuição e reprodução em qualquer meio, desde que a obra original é devidamente citada. Fonte:<http://www.jnanobiotechnology.com/content/9/1/11>. Acesso em: 03 fev. 2015.info:eu-repo/semantics/openAccessFree rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleMamas - câncer - tratamentoQuimioterapiaengreponame:Repositório Institucional da UnBinstname:Universidade de Brasília (UnB)instacron:UNBORIGINALARTIGO_FreeRhodiumCitrate.pdfARTIGO_FreeRhodiumCitrate.pdfapplication/pdf4637015http://repositorio2.unb.br/jspui/bitstream/10482/17627/1/ARTIGO_FreeRhodiumCitrate.pdf47a2992b3dc1727454a5c9729cd6f0b5MD51open accessLICENSElicense.txtlicense.txttext/plain266http://repositorio2.unb.br/jspui/bitstream/10482/17627/2/license.txt1554fabdb52f4d7ad979cffae637115eMD52open access10482/176272023-10-06 16:27:51.759open accessoai:repositorio.unb.br:10482/17627TGljZW5zZSBncmFudGVkIGJ5IEFuYSBDcmlzdGluYSBCYXJib3NhIGRhIFNpbHZhIChhbm5hYmRzQGhvdG1haWwuY29tKSBvbiAyMDE1LTAyLTAzVDE2OjI1OjIyWiAoR01UKToKClN1Ym1pc3PDo28gZWZldGl2YWRhIHBvciBpbnRlZ3JhbnRlIGRhIGVxdWlwZSBkbyBSZXBvc2l0w7NyaW8gSW5zdGl0dWNpb25hbCBkYSBVbkIgZGUgYWNvcmRvIGNvbSBsaWNlbsOnYSBjb25jZWRpZGEgcGVsbyBhdXRvciBlL291IGRldGVudG9yIGRvcyBkaXJlaXRvcyBhdXRvcmFpcy4=Repositório InstitucionalPUBhttps://repositorio.unb.br/oai/requestrepositorio@unb.bropendoar:2023-10-06T19:27:51Repositório Institucional da UnB - Universidade de Brasília (UnB) |
| spellingShingle | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy Carneiro, Marcella Lemos Brettas Mamas - câncer - tratamento Quimioterapia |
| status_str | publishedVersion |
| title | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| title_full | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| title_fullStr | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| title_full_unstemmed | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| title_short | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| title_sort | Free rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy |
| topic | Mamas - câncer - tratamento Quimioterapia |
| url | http://repositorio.unb.br/handle/10482/17627 |